A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
Latest Information Update: 23 May 2024
Price :
$35 *
At a glance
- Drugs Pracinostat (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms PRIMULA
- Sponsors Helsinn
- 01 May 2024 Results evaluating the efficacy/safety of pracinostat administered with AZA in adult patients with newly diagnosed AML ineligible to receive IC, published in the Leukemia Research
- 03 Apr 2022 This trial has been completed in Hungary (Date of the global end of the trial : 02-Jul-2020), according to European Clinical Trials Database record.
- 02 Jul 2020 According to a Helsinn media release, Primary endpoint (Overall survival) has not been met.